These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31879018)

  • 1. [Thyroid dysfunctions secondary to cancer immunotherapy].
    Cugnet Anceau C; Abeillon J; Maillet D; Borson-Chazot F; Disse E
    Bull Cancer; 2020 Feb; 107(2):262-271. PubMed ID: 31879018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.
    Lee H; Hodi FS; Giobbie-Hurder A; Ott PA; Buchbinder EI; Haq R; Tolaney S; Barroso-Sousa R; Zhang K; Donahue H; Davis M; Gargano ME; Kelley KM; Carroll RS; Kaiser UB; Min L
    Cancer Immunol Res; 2017 Dec; 5(12):1133-1140. PubMed ID: 29079654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expert opinion on thyroid complications in immunotherapy.
    Illouz F; Drui D; Caron P; Do Cao C
    Ann Endocrinol (Paris); 2018 Oct; 79(5):555-561. PubMed ID: 30126627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common thyroid disorders.
    Sakiyama R
    Am Fam Physician; 1988 Jul; 38(1):227-38. PubMed ID: 3293385
    [No Abstract]   [Full Text] [Related]  

  • 5. Thyroid dysfunctions secondary to cancer immunotherapy.
    Chalan P; Di Dalmazi G; Pani F; De Remigis A; Corsello A; Caturegli P
    J Endocrinol Invest; 2018 Jun; 41(6):625-638. PubMed ID: 29238906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
    Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
    Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.
    Jannin A; Penel N; Ladsous M; Vantyghem MC; Do Cao C
    Crit Rev Oncol Hematol; 2019 Sep; 141():23-35. PubMed ID: 31202955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Subclinical thyroid dysfunction].
    Goichot B; Luca F
    Presse Med; 2011 Dec; 40(12 Pt 1):1132-40. PubMed ID: 22115677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy.
    Brilli L; Danielli R; Campanile M; Secchi C; Ciuoli C; Calabrò L; Pilli T; Cartocci A; Pacini F; Di Giacomo AM; Castagna MG
    J Endocrinol Invest; 2021 Aug; 44(8):1719-1726. PubMed ID: 33367977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Autoimmune hypophysitis associated with new anti-cancer immunotherapies].
    Jannin A; Merlen E; Do Cao C; Penel N
    Bull Cancer; 2018 Mar; 105(3):275-280. PubMed ID: 29475597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
    Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
    Ferrari SM; Fallahi P; Elia G; Ragusa F; Ruffilli I; Patrizio A; Galdiero MR; Baldini E; Ulisse S; Marone G; Antonelli A
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies.
    Orlov S; Salari F; Kashat L; Walfish PG
    J Clin Endocrinol Metab; 2015 May; 100(5):1738-41. PubMed ID: 25751110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients.
    Campredon P; Mouly C; Lusque A; Bigay-Game L; Bousquet E; Mazières J; Caron P
    Presse Med; 2019 Apr; 48(4):e199-e207. PubMed ID: 31005502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CME: Thyrotoxicosis and Thyroiditis].
    Slahor L
    Praxis (Bern 1994); 2018; 107(22):1187-1192. PubMed ID: 30376773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid diseases in elderly.
    Faggiano A; Del Prete M; Marciello F; Marotta V; Ramundo V; Colao A
    Minerva Endocrinol; 2011 Sep; 36(3):211-31. PubMed ID: 22019751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current questions of thyroid diseases in childhood].
    Ilyés I
    Orv Hetil; 2011 Apr; 152(16):617-27. PubMed ID: 21454178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
    Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
    J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of thyroid disorders.
    McGuinness ME; Talbert RL
    Am Pharm; 1994 Dec; NS34(12):36-47. PubMed ID: 7856507
    [No Abstract]   [Full Text] [Related]  

  • 20. Over-the-counter-drug-induced thyroid disorders.
    Hoang TD; Mai VQ; Clyde PW; Shakir MK
    Endocr Pract; 2013; 19(2):268-74. PubMed ID: 23529350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.